Fig. 5: Influence of MEK5 activity-inhibition on cell cycle progression.
From: Clinical, genetic and pharmacological data support targeting the MEK5/ERK5 module in lung cancer
a Cell cycle profile of H460 cells treated with 5 µM BIX02189 and analyzed by FACS at 24 h. Results are expressed as mean percentage of cells in each cell cycle phase ± SD of an experiment that was repeated three times. *p ≤ 0.05; **p ≤ 0.01 for the statistical comparison between the same cell cycle phases of control or BIX02189-treated samples. Exact p-values are shown in Supplementary Table 1d. b BrdU incorporation was coupled to 7-ADD staining and measured at 24 h using the FITC BrdU Flow Kit to precisely define the percentage of cells undergoing DNA synthesis. c H460 cells were synchronized in mitosis by nocodazole. Mitotic cells were released from nocodazole block in the absence or presence of 5 µM BIX02189 for the indicated times and the effect of the drug on the different phases of cell cycle was analyzed by FACS, and d proteins implicated in cell cycle progression were evaluated by western blotting with the indicated antibodies. GAPDH was used as loading control. e H460 cells were either untreated or treated with 5 μM BIX02189 for 72 h and apoptosis was analyzed by Annexin V-FITC assay.
